xm:楼丽广
xb:男
zc:研究员
xl:博士
dh:86-
cz:86-
dzyj:lglou@mail.shcnc.ac.cn
grzy:
zjlb:研究员
zw:研究组长、博士生导师
txdz:上海市祖冲之路555号
grjj:1967年2月出生在浙江省永康市。1993年毕业于河南医科大学，获药理学硕士学位。1996年毕业于中国科学院上海药物研究所，获药理学博士学位。1996年至1998年在中国科学院上海细胞生物学研究所从事博士后研究。2000年至2002年在美国University of Pittsburgh药理学系接受博士后训练。2002年7月起在中国科学院上海药物研究所从事科研工作。现任中国科学院上海药物研究所研究员，博士生导师，肿瘤药理实验室课题组长。

yjfx:抗肿瘤创新药物临床前药效评价及作用机制研究。

dblz:1.Xiang-ling Chen, Peng Liu, Wei-liang Zhu and Li-guang Lou*. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy,exerts antitumor activity against colon cancer. Acta Pharmacol Sin. 2020; in press.

2.Chen L, Quan H, Xu Z, Wang H, Xia Y, Lou L*, Yang W*. A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation. Nat Commun 2020(11):2151.

3.Mengya Tong, Mingzhao Gao, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Haitian Quan* and Liguang Lou*. SHR-A1403, a novel c-Met antibody-drug conjugate, overcomes AZD9291 resistance in NSCLC cells overexpressing c-Met. Cancer Science, 2019,110(11):3584-3594.

4.Mingzhao Gao, Hongmei Zhu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Haitian Quan, Lei Wang*, Liguang Lou*. Pharmacologic Characterization of TQ05310, a Potent Inhibitor of Isocitrate Dehydrogenase 2 (IDH2) R140Q and R172K mutants. Cancer Science, 2019：3306-3314.

5.Liu CP, Xie CY, Zhao JX, Ji KL, Lei XX, Sun H*, Lou LG*, Yue JM*. Dysoxylactam A: A Macrocyclolipopeptide Reverses P-Glycoprotein-Mediated Multidrug Resistance in Cancer Cells. J Am Chem Soc. 2019(141):6812-6816.

6.Fei Long, Ye He, Haoyu Fu, Yun Li, Xubin Bao, Quanren Wang, Yigang Wang*, Chengying Xie*, Liguang Lou*. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sciences 2019; 1420-1430.

7.Lei Wang, Changyong Yang, Chengying Xie, Jiahua Jiang, Mingzhao Gao, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Liguang Lou*. Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials. Cancer Sciences 2019; 1064-1075..

8.Lei Wang#, Mingzhao Gao#, Mengya Tong, Chengying Xie, Ye He, Li Fu, Yun Li, Haoyu Fu, Liguang Lou*. Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. Am J Cancer Res 2018;8(8):1541-1550.

9.Chengying Xie, Huajun Zhao, Xubin Bao, Haoyu Fu, and Liguang Lou *. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. JCMM 2018；5367-5377

10.Lei Wang, Quanren Wang, Mingzhao Gao, Li Fu, Yun Li, Haitian Quan, Liguang Lou*. STAT3 Activation Confers Trastuzumab-Emtansine (T-DM1) Resistance in HER2-positive Breast Cancer. Cancer Sciences 2018;3305-3315

11.Xiangling Chen, PengLiu, QuanrenWang, Yun Li, LiFu, Haoyu Fu, Jianming Zhu, Zhaoqiang Chen, Weiliang Zhu, Chengying Xie, Liguang LOU*. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction. Cancer Letters 2018; 434:70-80

12.Ming-zhao Gao, Hong-bin Wang, Xiang-ling Chen, Wen-ting Cao, Li Fu, Yun Li, Hai-tian Quan, Cheng-ying Xie and Li-guang Lou*. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Acta Pharmaco Sinica, 2018:268-278.

13.Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou*. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Science, 2018；1207-1219

14.Ye He, Liping Sun, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Chengying Xie* and Liguang Lou*. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia. Cancer Letters 2018; 420:49-59

jyjl:09/01/1990 - 07/31/1993河南医科大学，肿瘤药理，硕士